登录新浪财经APP 搜索【信披】查看更多考评等级 国药集团一致药业股份有限公司 第十届董事会2025年第七次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 国药集团一致药业股份有限公司（以下简称"公司"或"国药一致"） 第十届董事会2025年第七次临时会 议于2025年11月24日以电子邮件方式发出通知和文件材料，会议于2025年11月27日以通讯表决方式召 开。应参加会议董事9名，亲自出席会议董事9名。会议召开程序符合《公司法》、《公司章程》的有关 规定。 二、董事会会议审议情况 1. 审议通过了《关于审议〈国药一致估值提升计划〉的议案》 表决结果：9票同意，0票反对，0票弃权。 具体内容详见公司在巨潮资讯网披露的相关公告。 证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2025-41 2.审议通过了《关于修订〈国药一致董事会战略委员会工作制度〉的议案》 表决结果：9票同意，0票反对，0票弃权。 具体内容详见公司在巨潮资讯网披露的相关公告。 3.审议通过了《关于制定〈国药一致环境、社会及 ...

Summary of the Conference Call for Guoyao Yizhi Company Overview - **Company**: Guoyao Yizhi - **Period**: First half of 2025 Key Financial Performance - Total revenue decreased by 2.62% to 36.797 billion yuan [3] - Net profit attributable to shareholders fell by 10.43% to 666 million yuan [3] - Total assets increased slightly to 550.426 billion yuan, with a stable debt ratio of 57.86% [3] - Earnings per share decreased by 10% to 1.2 yuan [3] - Operating cash flow declined significantly, attributed to extended receivables and negative sales growth in retail [15][16] Distribution Segment Performance - Distribution revenue decreased by 1.09% to 26.783 billion yuan, with net profit down by 7.82% [5] - High-margin products such as biological products, narcotic drugs, and innovative drugs showed strong growth [5] - Collaboration in the Hong Kong and Macau regions was emphasized, along with the integration of new products and innovative drug business [5] - The company expects distribution segment performance to remain stable compared to 2024, despite pressures from procurement expansion and healthcare payment reforms [9] Retail Segment Performance - Retail revenue from Guoda Pharmacy decreased by 6.46% to 10.479 billion yuan, but net profit surged by 215.81% to 17 million yuan [5] - The improvement in net profit was due to continuous optimization of product structure and business model, as well as enhanced operational efficiency [5] - Approximately 1,000 stores were closed to optimize layout, resulting in a total of 8,591 stores by the end of June 2025 [8] Digital Transformation and Smart Logistics - The company implemented digital tools to enhance operational efficiency and management [6] - A "1+4+N" warehouse network layout was established to improve storage capacity and efficiency [6] Organizational Changes and Talent Development - Organizational restructuring was undertaken to enhance resource integration and talent development [7] - Performance and incentive mechanisms were optimized to align with company goals [7] Credit Impairment Losses - Credit impairment losses increased significantly due to extended payment terms and high revenue scale [12] - The company plans to strengthen credit management and control high-risk clients [12][25] Future Strategies and Market Outlook - The company aims to expand its narcotic qualifications and enhance regional coverage [10] - Confidence in increasing market share in Guangxi and Guangdong, despite competitive pressures [11][18] - Focus on improving operational quality and cash flow management in a competitive environment [18] Industry Trends and Challenges - The retail pharmacy sector is expected to face challenges due to increased management and competition, but long-term value remains [17] - The company will continue to adapt to market changes and enhance operational capabilities [17] Conclusion - Guoyao Yizhi is navigating a challenging environment with a focus on optimizing operations, enhancing digital capabilities, and maintaining a stable market presence while addressing credit risks and adapting to industry changes. The outlook remains cautiously optimistic with strategic initiatives aimed at improving profitability and market share.

本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 國藥集團一致藥業股份有限公司 2025 年半年度業績快報 茲載列國藥控股股份有限公司旗下一間 A 股及 B 股於深圳證券交易所上市的附屬公司，國藥集 團一致藥業股份有限公司，在深圳證券交易所網站刊登的《國藥集團一致藥業股份有限公司 2025 年半年度業績快報》，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 14 日 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2025-34 国药集团一致药业股份有限公司 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉 ...

Financial Performance - Total revenue for the reporting period was ¥37,785,980,620.95, a decrease of 1.57% compared to the same period last year[11]. - Net profit attributable to shareholders was ¥743,487,174.84, down 10.45% year-on-year[11]. - Basic earnings per share decreased by 10.07% to ¥1.34[11]. - Net cash flow from operating activities was ¥929,377,508.78, a decline of 37.47% compared to the previous year[11]. - The company reported a net profit of ¥711,378,482.12, down 10.48% from the previous year[11]. - In the first half of 2024, the company achieved operating revenue of CNY 37.786 billion, a year-on-year decrease of 1.57%, and a net profit attributable to shareholders of CNY 743 million, down 10.45%[22]. - The distribution segment generated operating revenue of CNY 27.079 billion, an increase of 2.11% year-on-year, while net profit was CNY 523 million, a decrease of 1.48%[22]. - The retail segment (Guoda Pharmacy) reported operating revenue of CNY 11.202 billion, a decline of 9.30% year-on-year, with a net profit of -CNY 14 million, down 104.81%[22]. - The company reported a total of non-recurring gains and losses amounting to ¥32,108,692.72[14]. - The company reported a significant decrease in net profit for its subsidiary, Guoda Pharmacy, by 104.81% due to industry policy changes and increased market competition[51]. Assets and Liabilities - Total assets increased by 8.06% to ¥51,405,241,387.83 at the end of the reporting period[11]. - Net assets attributable to shareholders rose by 2.10% to ¥17,779,820,945.40[11]. - The total accounts receivable amounted to ¥22,459,134,687.56, accounting for 43.69% of total assets, an increase of 5.51% from the previous year[42]. - The total inventory at the end of the reporting period was ¥8,381,354,048.18, accounting for 16.30% of total assets, a slight decrease of 0.49% from the previous year[42]. - The company’s short-term borrowings increased to ¥4,441,325,969.54, representing 8.64% of total assets, an increase of 3.15% from the previous year[42]. - Total liabilities reached CNY 30.06 billion, up 13.8% from CNY 26.59 billion at the beginning of the year[109]. - The company's total current liabilities amounted to CNY 27.67 billion, an increase of 13.5% from CNY 24.34 billion[109]. Market and Business Strategy - The company is focusing on transforming its retail model to enhance service quality and reduce reliance on individual account medical insurance payments[17]. - The company aims to integrate its distribution and logistics operations to create a leading supply chain value system in the pharmaceutical industry[18]. - The company is committed to enhancing its professional pharmaceutical service capabilities through partnerships with leading suppliers[18]. - The company is focusing on digital transformation, having launched a business value analysis tool and a collaborative platform to enhance data integration and decision-making[24]. - The company is actively expanding its logistics capabilities, achieving AAAA-level certification as a comprehensive service logistics enterprise[24]. - The company is focusing on enhancing risk management and compliance training to ensure sustainable development[29]. - The company is expanding its online sales through a multi-channel approach, including O2O models and live streaming marketing[29]. - The company is investing heavily in R&D, with a budget allocation of 1,500 million for new technologies and product development[84]. - The company is actively pursuing mergers and acquisitions to strengthen its market position, with a focus on integrating new technologies[91]. Compliance and Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[2]. - The company is committed to compliance and risk management, which is expected to strengthen its competitive position in the market[21]. - The company faces significant policy risks, including declining sales margins due to centralized procurement and increased competition from online pharmacies[53]. - The company is experiencing increased compliance risks due to regulatory changes and heightened scrutiny in the pharmaceutical sector[54]. - The company has reported a total of 117 legal disputes during the reporting period, with a total amount involved of 176.18 million yuan[67]. - The company has established environmental emergency response plans and conducted regular drills to enhance emergency response capabilities[64]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares[2]. - The company has a total of 556,565,077 shares, with 98.71% being unrestricted shares[96]. - The largest shareholder, China National Pharmaceutical Group Co., Ltd., holds 56.06% of the shares, totaling 311,999,988 shares[97]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[103]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[60]. Future Outlook - The company has provided a performance guidance for the second half of 2024, projecting a revenue growth of approximately 15% year-over-year[84]. - Future guidance includes a projected revenue increase of 20% for the next quarter, reflecting confidence in market expansion strategies[92]. - Overall, the company remains optimistic about future growth, citing strong demand in key segments and a robust pipeline of new products[84]. - The company is focusing on enhancing its core competitiveness and exploring new growth opportunities amid a challenging market environment[55]. Financial Reporting and Accounting Practices - The financial statements for the first half of 2024 were approved by the board on August 27, 2024, ensuring compliance with accounting standards[141]. - The company adheres to the accounting principles established by the Ministry of Finance, ensuring accurate financial reporting and transparency[138]. - The company recognizes expected credit losses based on the present value of cash flow differences between contractual receivables and expected cash flows, considering reasonable and supportable information[153]. - The company recognizes revenue when control of goods or services is transferred to customers, typically at the point of customer acceptance[190]. - The company has established special reserve funds and materials for emergency responses, funded by the government, and manages these reserves dynamically[197].

Financial Performance - The company's operating revenue for 2023 reached ¥75.48 billion, an increase of 2.77% compared to ¥73.44 billion in 2022[19]. - Net profit attributable to shareholders for 2023 was ¥1.60 billion, reflecting a growth of 7.57% from ¥1.49 billion in 2022[19]. - The net cash flow from operating activities increased by 14.71% to ¥2.94 billion, up from ¥2.56 billion in the previous year[19]. - Basic earnings per share for 2023 were ¥2.87, a 7.49% increase from the adjusted ¥2.67 in 2022[19]. - Total assets at the end of 2023 amounted to ¥47.57 billion, marking an 11.63% increase from ¥42.62 billion at the end of 2022[19]. - The net assets attributable to shareholders increased by 7.99% to ¥17.41 billion, compared to ¥16.13 billion at the end of 2022[19]. - The total profit for 2023 was 2.473 billion yuan, an increase of 7.02% compared to the previous year[48]. - The net profit for 2023 reached 1.958 billion yuan, reflecting a year-on-year growth of 10.54%[48]. - The distribution business generated revenue of 51.957 billion yuan in 2023, with a year-on-year increase of 3.50%[48]. - The retail business, represented by Guoda Pharmacy, achieved revenue of 24.409 billion yuan, growing by 1.26% year-on-year[49]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of ¥6.8 per 10 shares, totaling approximately ¥556.57 million based on the current share base[3]. - In 2023, the company distributed cash dividends of RMB 8.00 per 10 shares, totaling RMB 378,464,252.36, which represents 100% of the profit distribution amount[157]. Market and Industry Trends - The average price reduction from the eighth and ninth batches of national drug procurement was 56% and 58%, respectively, contributing to significant cost savings in the healthcare sector[31]. - The national medical insurance drug list was adjusted to include 3,088 types of drugs, with 126 new drugs added in 2023, indicating a growing range of available treatments[32]. - The pharmaceutical retail market is projected to exceed CNY 800 billion by 2030, with retail channels expected to account for 40% of the market share[101]. - The company is positioned to benefit from ongoing healthcare reforms and increased government support for the pharmaceutical industry, particularly in the Guangdong-Hong Kong-Macao Greater Bay Area[30]. Operational Developments - The company has established four large automated logistics centers and 23 distribution centers, enhancing its logistics network in the Guangdong region[45]. - The company is actively pursuing digital transformation, integrating AI, big data, and 5G technologies into its supply chain solutions[45]. - The company is adapting to new policies allowing retail pharmacies to sell non-pharmaceutical products, which will enhance profitability and counteract the impact of declining drug prices[41]. - The company is focusing on a diversified service transformation strategy, enhancing its service capabilities and maintaining a leading market share in the pharmaceutical distribution sector[44]. Research and Development - The company completed six R&D projects in 2023, focusing on cold chain, operational metrics, visual recognition, and customer service[52]. - Total R&D expenses increased by 195.81% to ¥26,821,075.48 in 2023 from ¥9,066,902.05 in 2022[84]. - The number of R&D personnel rose by 162.50% to 126 in 2023, compared to 48 in 2022[85]. - The company is investing heavily in R&D, with a budget allocation of 500 million RMB for new drug development[130]. Risk Management and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[3]. - The company is committed to compliance and maintaining competitive advantages amid stringent regulatory environments in the pharmaceutical industry[103]. - The company is addressing cash flow risks due to prolonged payment cycles and increased financing costs resulting from economic slowdowns[105]. - The company has implemented a robust internal control system that includes risk identification and management measures[160]. Corporate Governance - The company operates independently from its controlling shareholders in terms of business, personnel, assets, and finance, ensuring complete operational autonomy[116]. - The company has established an independent financial department and accounting system, with no financial personnel holding positions or receiving compensation from the controlling shareholders[118]. - The company has a complete governance structure with distinct roles for the board of directors, supervisory board, and management team[116]. - The company has a diverse leadership team, with members having extensive backgrounds in the pharmaceutical industry, including over 27 years of experience for the president, Liu Yong[125]. Environmental and Social Responsibility - The company has not faced any administrative penalties related to environmental issues during the reporting period[167]. - All key pollution monitoring units have established pollution prevention facilities and are continuously investing in upgrades to enhance their capabilities[168]. - The company's 2023 ESG report will be released alongside the Q1 2024 report, providing insights into its environmental and social responsibility efforts[170].

Financial Performance - The company's revenue for Q3 2023 was CNY 18.20 billion, a decrease of 1.57% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was CNY 359.41 million, down 3.75% year-on-year[5]. - For the first nine months of 2023, the company achieved a total revenue of CNY 56.59 billion, an increase of 3.61% year-on-year[6]. - The retail segment reported revenue of CNY 17.72 billion for the first nine months, growing by 6.37%, with net profit increasing by 80.27%[6]. - The distribution segment generated revenue of CNY 39.57 billion, a year-on-year increase of 2.43%, but net profit decreased by 0.57%[6]. - Total operating revenue for the third quarter reached ¥56.59 billion, an increase of 3.6% compared to ¥54.62 billion in the same period last year[21]. - Total operating costs amounted to ¥54.98 billion, up 3.4% from ¥53.17 billion year-on-year[21]. - Net profit for the quarter was ¥1.45 billion, representing a 19.0% increase from ¥1.22 billion in the previous year[22]. - Earnings per share (EPS) for the quarter was ¥2.14, compared to ¥1.88 in the same period last year, reflecting a growth of 13.8%[22]. - The total comprehensive income for the quarter was ¥1.45 billion, compared to ¥1.22 billion, reflecting a growth of 18.8% year-on-year[22]. Assets and Liabilities - The company's total assets as of the end of Q3 2023 were CNY 50.74 billion, reflecting a growth of 19.06% compared to the previous year[5]. - As of September 30, 2023, total assets reached CNY 50.74 billion, an increase from CNY 42.62 billion at the beginning of the year, reflecting a growth of approximately 18.5%[18]. - Current assets amounted to CNY 39.70 billion, up from CNY 31.71 billion at the start of the year, indicating a growth of about 25.1%[18]. - The total liabilities increased to ¥30.27 billion, up from ¥23.17 billion, indicating a growth of 30.5% year-on-year[21]. - The total liabilities of the company were not explicitly stated but can be inferred to have increased in line with asset growth, indicating potential leverage[18]. Cash Flow - Cash flow from operating activities for the first nine months was CNY 1.47 billion, a decrease of 28.78% year-on-year[5]. - Cash received from operating activities increased by CNY 198.30 million, a growth of 40.98%, due to increased receipts from reserve funds and deposits[12]. - The cash inflow from operating activities for the period was CNY 53,825,819,839.45, a decrease of 4.3% compared to CNY 56,601,974,140.25 in the previous period[23]. - The net cash flow from operating activities was CNY 1,465,469,101.73, down 28.8% from CNY 2,057,795,818.15 in the same period last year[23]. - The cash inflow from financing activities was CNY 1,420,106,804.21, down 16.5% from CNY 1,701,018,741.55 in the previous period[24]. - The net cash flow from financing activities was -CNY 2,014,650,640.63, worsening from -CNY 942,013,590.74 in the previous period[24]. - The total cash and cash equivalents at the end of the period stood at CNY 4,827,559,248.03, down from CNY 5,732,553,872.11 in the previous period[24]. Investments and Expenses - R&D expenses increased by CNY 17.96 million, a growth of 100%, due to expenditures on medical management and smart service platform development[11]. - Research and development expenses for the quarter were ¥17.96 million, indicating ongoing investment in innovation[21]. - Investment income increased by CNY 115.49 million, a growth of 103.50%, mainly from reduced receivables factoring and improved performance of joint ventures[11]. - The company reported an investment income of ¥227.06 million, significantly higher than ¥111.58 million from the previous year, showing a growth of 103.5%[21]. Market Outlook - The company is focusing on expanding its market presence and enhancing product development, although specific new products or technologies were not detailed in the report[17]. - Future outlook remains positive with expectations of continued growth in both revenue and market share, driven by strategic initiatives and potential acquisitions[17]. Accounts Management - The company reported a significant increase in accounts receivable, which rose by 68.65% compared to the beginning of the year, primarily due to delayed payments from downstream customers[10]. - Accounts receivable increased significantly to CNY 23.21 billion from CNY 13.76 billion, representing a rise of approximately 68.5%[18]. - Accounts payable increased by CNY 4,252.59 million, a growth of 51.81%, driven by increased business volume and procurement[11]. - The company reported a significant increase in receivables, which may indicate strong sales performance but also raises concerns about cash flow management[18].

证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2023-23 国药集团一致药业股份有限公司 第九届董事会第十四次会议决议公告 本公司及董事全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 国药集团一致药业股份有限公司（以下简称"公司"或"国药一致"） 第九届董事会第十四次会议于2023年8月14日以电话、传真和电子邮 件方式发出通知和文件材料，会议于2023年8月25日以现场会议（结 合视频会议）方式在广州+上海召开。董事长林敏先生主持会议。应 参加会议董事10名，亲自出席会议董事10名。公司监事、高管列席了 会议。会议召开程序符合《公司法》、《公司章程》的有关规定。本 次会议听取了公司总经理2023年半年度工作报告及国大药房总经理 2023年上半年管控提升情况汇报，审议了下列事项并形成相关决议。 为优化物流一体化运作，优化组织管理架构，提高运营效率和管 理水平，董事会同意由公司全资孙公司国药控股广东物流有限公司 （简称"国控广东物流"）吸收合并全资子公司国药控股深圳物流有 限公司（以下简称"国控深圳物流"）全部资产、负债、权益、人员及 业务（ ...

证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2023-24 国药集团一致药业股份有限公司 第九届监事会第十二会议决议公告 本公司及监事全体人员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 二、审议通过了《关于全资子公司与全资孙公司之间吸收合并的 议案》 三、审议通过了《关于对国药集团财务有限公司的风险持续评估 报告》 四、审议通过了《关于会计政策变更的议案》 以上议案均 3 票同意，0 票反对，0 票弃权。 特此公告。 国药集团一致药业股份有限公司监事会 2023年8月29日 公司第九届监事会第十二次会议于2023年8月14日以电话、传真 和电子邮件方式发出通知和文件材料，会议于2023年8月25日以现场 会议（结合视频会议）方式在广州+上海召开，监事会主席文德镛先 生主持会议。会议应参会监事3人，实际参会监事3人。会议召开程序 符合《公司法》、《公司章程》的有关规定。监事列席了第九届董事会 第十四次会议。会议审议并通过了下列议案： 一、审议通过了《公司2023年半年度报告及摘要》 ...

Financial Performance - The company's revenue for Q1 2023 reached CNY 18.69 billion, an increase of 8.96% compared to CNY 17.15 billion in the same period last year[5] - Net profit attributable to shareholders was CNY 362.21 million, reflecting a year-on-year growth of 43.53% from CNY 252.36 million[5] - The net profit after deducting non-recurring gains and losses was CNY 351.79 million, up 45.22% from CNY 242.24 million year-on-year[5] - Basic earnings per share increased by 44.07% to CNY 0.85 from CNY 0.59 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 18,686,817,786.50, an increase of 8.93% compared to CNY 17,150,856,946.54 in Q1 2022[20] - Operating costs for Q1 2023 amounted to CNY 18,166,841,198.40, up from CNY 16,797,706,856.47 in the same period last year, reflecting a growth of 8.14%[20] - Net profit for Q1 2023 reached CNY 460,830,788.65, representing a 56.36% increase from CNY 294,771,604.63 in Q1 2022[21] - Operating profit increased by CNY 201.27 million, a growth rate of 53.66%, mainly due to expanded sales scale and optimized business structure, leading to an increase in gross profit margin[11] - Net profit increased by CNY 166.06 million, a growth rate of 56.33%, driven by expanded sales scale and improved business structure[20] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of CNY 209.99 million, a significant turnaround from a negative cash flow of CNY 217.45 million in the previous year[5] - Cash flow from operating activities increased by CNY 427.44 million, a growth rate of 196.57%, due to adjustments in settlement methods and cycles[32] - The company's cash flow from operating activities showed a significant improvement, contributing positively to the overall financial health[22] - Total cash inflow from operating activities was 15,723,524,491.66 CNY, down 7.0% from 16,903,855,556.67 CNY in the prior period[23] - Cash outflow from operating activities decreased to 15,513,539,023.33 CNY from 17,121,307,780.05 CNY, reflecting a reduction of 9.4%[23] - The net cash flow from investing activities was -69,033,448.77 CNY, an improvement from -94,260,921.92 CNY in the previous period[24] - Cash inflow from financing activities totaled 566,164,144.13 CNY, down 25.1% from 755,291,223.35 CNY in the prior period[24] - The net cash flow from financing activities was -82,583,637.41 CNY, compared to a positive 112,007,819.57 CNY in the previous period[24] - The ending balance of cash and cash equivalents was 5,500,542,685.89 CNY, an increase from 4,533,806,395.75 CNY in the prior period[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 47.89 billion, representing a 12.36% increase from CNY 42.62 billion at the end of the previous year[5] - The company's total assets increased to CNY 47,885,197,936.57 in Q1 2023, compared to CNY 42,615,760,577.42 in Q1 2022, marking a growth of 12.67%[19] - Total liabilities rose to CNY 27,998,280,101.09 in Q1 2023, up from CNY 23,171,053,907.57 in Q1 2022, indicating a 20.00% increase[19] - The total current assets as of March 31, 2023, amounted to CNY 36,929,433,752.58, an increase from CNY 31,708,246,272.74 at the beginning of the year, representing a growth of approximately 16.9%[17] Shareholder Information - The company reported a total of 10 major shareholders, with the largest being China National Pharmaceutical Group holding 56.06% of shares[15] - The company has a total of 239,999,991 shares held by China National Pharmaceutical Group, which is subject to limited sale conditions[15] - The total number of shares held by the top 10 unrestricted shareholders is 234,494,221[15] Research and Development - Research and development expenses doubled to CNY 222.98 million, reflecting the company's investment in medical management and smart service platform development[10] - Research and development expenses were recorded at CNY 2,229,800.69, highlighting the company's commitment to innovation[20] Market Strategy - The company is focused on expanding its market presence and enhancing its product offerings through new technologies and research initiatives[16] - The financial report indicates a strategic emphasis on improving liquidity and managing receivables effectively to support future growth[16]

Financial Performance - The company's operating revenue for 2022 was approximately ¥73.44 billion, representing a 7.44% increase compared to ¥68.36 billion in 2021[19]. - The net profit attributable to shareholders for 2022 was approximately ¥1.49 billion, an increase of 11.24% from ¥1.34 billion in 2021[19]. - The net cash flow from operating activities increased by 54.69% to approximately ¥2.56 billion in 2022, compared to ¥1.66 billion in 2021[19]. - Basic earnings per share for 2022 were ¥3.47, up 11.22% from ¥3.12 in 2021[19]. - Total assets at the end of 2022 were approximately ¥42.62 billion, a slight decrease of 0.39% from ¥42.78 billion at the end of 2021[19]. - The net assets attributable to shareholders increased by 8.05% to approximately ¥16.13 billion at the end of 2022, compared to ¥14.92 billion at the end of 2021[19]. - The company reported a weighted average return on equity of 9.59% for 2022, an increase of 0.30 percentage points from 9.29% in 2021[19]. - The total profit for 2022 was 2.311 billion yuan, reflecting a year-on-year growth of 17.02%[42]. - The distribution business generated an operating revenue of 50.199 billion yuan, with a profit of 1.350 billion yuan, both showing year-on-year increases of 7.19% and 8.42% respectively[42]. - The retail segment, represented by Guoda Pharmacy, achieved an operating revenue of 24.106 billion yuan, with net profit soaring by 89.93% to 350 million yuan[42]. Market and Industry Trends - The pharmaceutical industry faced significant challenges in 2022, with over 320 new policies issued, indicating a transformative year for the sector[29]. - The national drug centralized procurement program has conducted 7 batches covering 294 drugs, achieving an average price reduction of over 50%[30]. - The implementation of the "dual-channel" policy is expected to enhance the role of retail pharmacies in the healthcare system, with ongoing reforms to improve their reimbursement capabilities[34]. - The company anticipates that the ongoing healthcare reforms will create both opportunities and challenges for retail pharmacies, particularly in terms of patient flow and reimbursement policies[34]. - The pharmaceutical industry is expected to shift towards innovation-driven development, with an emphasis on quality generic drugs and clinically valuable innovative drugs[105]. - The concentration of the pharmaceutical industry is projected to increase significantly, with the goal of cultivating 1-3 large-scale digitalized pharmaceutical distribution enterprises by 2025[106]. - The retail pharmacy sector is experiencing intensified competition, with a shift from price-based competition to differentiation as a key survival strategy[107]. Operational Efficiency and Innovations - The company’s logistics efficiency improved, with a reduction in single-item labor and transportation costs, while enhancing overall operational efficiency through the AIOCR automatic recognition system[47]. - The company has integrated advanced technologies in its operations, including smart equipment development and automation projects[54]. - The company is committed to accelerating transformation and upgrading, leveraging digital transformation to support business model evolution and operational changes[113]. - The company is focusing on digital transformation to enhance product value and achieve results, with an emphasis on improving digital management mechanisms and technical infrastructure[115]. - The company plans to enhance its digital platform, expecting a 30% increase in online sales by the end of the year[142]. Governance and Compliance - The company has maintained a robust governance structure, ensuring compliance with relevant laws and regulations, and enhancing operational efficiency[120]. - The company operates independently from its controlling shareholders in terms of business, personnel, and financial management, ensuring a complete separation of operations[121]. - The company has a clear asset ownership structure, with independent procurement and sales systems, safeguarding against asset encroachment by shareholders[123]. - The company is addressing potential competition issues with its controlling shareholders through formal agreements to mitigate conflicts in the retail pharmacy sector[124]. - The company has committed to maintaining the rights of all shareholders and ensuring transparency in its operations[186]. Employee and Management Structure - The total number of employees at the end of the reporting period is 39,296, with 118 in the parent company and 39,178 in major subsidiaries[156]. - The professional composition includes 29,287 sales personnel, 375 technical staff, and 804 financial personnel, among others[156]. - The company emphasizes a salary policy that aligns compensation with organizational performance, employee capabilities, and market conditions[157]. - The company has established a backup talent pool of 294 individuals, including 132 management-type, 35 technical-type, and 127 innovative-type talents, to support high-quality development during the 14th Five-Year Plan[159]. Environmental Responsibility - The company has implemented environmental monitoring plans and conducted regular self-inspections and third-party assessments[174]. - The company has completed environmental impact assessments for all key regulatory projects and obtained necessary approvals[174]. - The company has developed emergency response plans for environmental incidents and conducts regular drills[174]. - The company emphasizes energy conservation by improving equipment management and replacing lighting with energy-efficient options[177]. Future Outlook and Strategic Plans - The company provided a positive outlook for the next quarter, projecting a revenue growth of 12% to 15%[136]. - New product launches are expected to contribute an additional 1 billion RMB in revenue over the next fiscal year[137]. - Market expansion plans include entering three new provinces, aiming for a 10% market share in these regions within two years[139]. - The company is considering strategic acquisitions to enhance its product portfolio, targeting a deal valued at approximately 500 million RMB[140].